

Design, synthesis, and biological evaluation of the analogues of glaziovianin A, a potent antitumor isoflavone

著者別名	早川 一郎, 臼井 健郎, 木越 英夫
journal or publication title	Bioorganic & medicinal chemistry
volume	20
number	19
page range	5745-5756
year	2012-10
権利	(C) 2012 Elsevier Ltd. NOTICE: this is the author's version of a work that was accepted for publication in Bioorganic & medicinal chemistry. Changes resulting from the publishing process, such as peer review, editing, corrections, structural formatting, and other quality control mechanisms may not be reflected in this document. Changes may have been made to this work since it was submitted for publication. A definitive version was subsequently published in PUBLICATION, 20(19),2012 DOI:10.1016/j.bmc.2012.08.005
URL	http://hdl.handle.net/2241/117846

doi: 10.1016/j.bmc.2012.08.005


Graphical Abstract

To create your abstract, type over the instructions in the template box below.
Fonts or abstract dimensions should not be changed or altered.

Design, synthesis, and biological evaluation of the analogues of glaziovianin A, a potent antitumor isoflavone

Leave this area blank for abstract info.

Ichiro Hayakawa,* Akiyuki Ikedo, Takumi Chinen, Takeo Usui, and Hideo Kigoshi*
Department of Chemistry, Graduate School of Pure and Applied Sciences, University of Tsukuba
Graduate School of Life and Environmental Sciences, University of Tsukuba





Design, synthesis, and biological evaluation of the analogues of glaziovianin A, a potent antitumor isoflavone

Ichiro Hayakawa,^{a*} Akiyuki Ikedo,^a Takumi Chinen,^b Takeo Usui,^b and Hideo Kigoshi^{a*}

^aDepartment of Chemistry, Graduate School of Pure and Applied Sciences, University of Tsukuba, Tennodai, Tsukuba, 305-8571, Japan

^bGraduate School of Life and Environmental Sciences, University of Tsukuba, Tennodai, Tsukuba, 305-8572, Japan

ARTICLE INFO

Article history:

Received

Received in revised form

Accepted

Available online

Keywords:

Structure–activity relationship study

Glaziovianin A

Isoflavone

Antitumor activity

Molecular probes

ABSTRACT

Various analogues of glaziovianin A, an antitumor isoflavone, were synthesized, and their biological activities were evaluated. *O*⁷-Modified glaziovianin A showed strong cytotoxicity against HeLa S₃ cells. Compared to glaziovianin A, the *O*⁷-benzyl and *O*⁷-propargyl analogues were more cytotoxic against HeLa S₃ cells and more potent M-phase inhibitors. Furthermore, *O*⁷-modified molecular probes of glaziovianin A were synthesized for biological studies.

2009 Elsevier Ltd. All rights reserved.

1. Introduction

Glaziovianin A (**1**), isolated from the leaves of the Brazilian tree *Ateleia glazioviana*, exhibited a broad spectrum of cytotoxicity against a panel of 39 human cancer cell lines (termed JFCR39) at the Japanese Foundation for Cancer Research (Figure 1).¹ On the basis of COMPARE analysis, the pattern of the differential cytotoxicities of glaziovianin A (**1**) suggested that glaziovianin A (**1**) inhibits cancer cell proliferation by inhibiting tubulin polymerization.² Indeed, we previously reported that glaziovianin A (**1**) arrested the cell cycle progression in M phase as do tubulin inhibitors.¹ Interestingly, glaziovianin A (**1**) induced abnormal spindle structures with unaligned chromosomes in mitotic cells, but did not influence on the microtubule network in interphase cells. Although the target molecule(s) or inhibitory mechanism remained to be revealed, these results suggest that glaziovianin A (**1**) is a novel mitotic inhibitor. Mitotic inhibitors including tubulin polymerization inhibitors have become clinically important drugs, especially against breast cancer.³ Also, glaziovianin A (**1**) showed antitumor activities in a mouse xenograft model (unpublished data). These results encouraged us to develop novel anticancer drugs based on glaziovianin A (**1**). A structure–cytotoxicity relationship study of glaziovianin A (**1**) was preliminarily reported by our group.⁴ In the present paper, we describe in detail the structure–activity relationships of glaziovianin A, specifically concerning its cytotoxicity and its effects on cell cycle progression and spindle structure. We also describe the synthesis of molecular probes of glaziovianin A for biological studies and target identification.





Figure 1. Structure of glaziovianin A (**1**).

We previously synthesized glaziovianin A (**1**) by using Suzuki–Miyaura coupling as a key step (Scheme 1).⁵ We used a similar strategy to synthesize glaziovianin A analogues. To develop these analogues, the structure of glaziovianin A (**1**) can be divided into two structural moieties: an A-ring and a B-ring (Figure 2). Therefore, we synthesized 3-iodochromone analogues as an A-ring and boron compounds as a B-ring.



Scheme 1. Total synthesis of glaziovianin A (**1**) by our group.







Figure 2. Key structural moieties of glaziovianin A.

2. Results and discussion

2.1. Synthesis of B-ring analogues of glaziovianin A

First, we prepared B-ring analogues of glaziovianin A (Scheme 2). The diol group in 3,6-dimethoxybenzene-1,2-diol (**6**)⁶ was protected as an acetonide group to give compound **7**. The bromination of **7** gave a monobromo compound, which was converted into arylboronate **8** by using PdCl₂(dppf), bis(pinacolato)diboron, and KOAc in DMF at 150 °C.⁷ The Suzuki–Miyaura coupling⁸ between 3-iodo-6,7-dimethoxy-4H-chromen-4-one (**3**)⁵ and boron compounds, such as arylboronate **8**, 2,3,4,5-tetramethoxyphenylboronic acid (**10**),⁹ or commercially available 3,4-(methylenedioxy)phenylboronic acid (**11**), gave glaziovianin A analogues **12–14**, respectively. On the


other hand, bromide **15** was synthesized from selective bromination at the C6' position of glaziovianin A (**1**).



Scheme 2. Synthesis of B-ring analogues of glaziovianin A. Reagents and conditions: (a) 2-methoxypropene, PPTS, benzene, reflux, 72%; (b) NBS, DMF, rt, 57%; (c) bis(pinacolato)diboron, PdCl₂(dppf), KOAc, DMF, 150 °C, 28%; (d) *n*-BuLi, B(OMe)₃, THF, rt; (e) **3**, PdCl₂(dppf), 1 M Na₂CO₃ aq., 1,4-dioxane, rt {64% for **12**, 11% for **13** (from **9**), 41% for **14**}; (f) NBS, DMF, rt, 31%.


2.2. Synthesis of A-ring analogues of glaziovianin A

Next, we tried to modify the A-ring part of glaziovianin A (Scheme 3). The hydroxy group at the C7 position of **16**¹⁰ was protected as a THP group to afford compound **17**. Condensation of **17** with *N,N*-dimethylformamide dimethyl acetal gave an enamine in quantitative yield. Iodination cyclization of the enamine afforded iodochromone **18**.¹¹ The cross coupling reaction of arylboronate **55** and iodochromone compounds **18** and **19**¹², gave glaziovianin A analogues **20** and **21**, respectively.



Scheme 3. Synthesis of glaziiovianin A analogues **20** and **21**. Reagents and conditions: (a) DHP, PPTS, CH₂Cl₂, rt, 80%; (b) Me₂NCH(OMe)₂, 90 °C, quant; (c) I₂, py, CHCl₃, rt, 75%; (d) **5**, PdCl₂(dppf), 1 M Na₂CO₃ aq., 1,4-dioxane, rt (66% for **20**, 16% for **21**)

Next, we attempted to synthesize glaziiovianin A analogues that have various functional groups at the C7 position (Scheme 4). Treatment of compound **20** with *p*-TsOH·H₂O provided *O*⁷-demethyl analogue **22**, which is a suitable precursor for the synthesis of *O*⁷-modified glaziiovianin A. Thus, we tried to synthesize glycoside **25** and diol **27** in order to improve water solubility. Glycosylation of the *O*⁷ position in **22** with tetraacetyl glucopyranosyl trichloroacetimidate **23** by using Schmidt glycosylation¹³ gave tetraacetyl glycosylisoflavone **24**. Removal of the acetyl groups of **24** by using NaOMe afforded glycoside **25**. Next, allylation of *O*⁷-demethyl analogue **22** with allyl bromide gave allyl ether **26**. Dihydroxylation of the terminal olefin of **26** afforded diol **27**. On the other hand, the hydroxy group at the C7 position in **22** was alkylated into benzyl ether **28** and propargyl ether **29** in order to increase lipid solubility.



Scheme 4. Synthesis of *O*⁷-modified analogues of glaziiovianin A. Reagents and conditions: (a) *p*-TsOH·H₂O, MeOH, CHCl₃, rt, 85%; (b) **23**, BF₃·Et₂O, MS3A, CH₂Cl₂, rt, 27% (α : β = 1 : 5.6); (c) NaOMe, MeOH, rt, 91%; (d) allyl bromide, K₂CO₃, MeCN, rt, 81%; (e) OsO₄, py, rt, 84%; (f) benzyl bromide, K₂CO₃, MeCN, rt, 80%; (g) propargyl bromide, K₂CO₃, MeCN, rt, 67%.

2.3. Cytotoxicity of glaziiovianin A (**1**) and its analogues against HeLa S₃ cells

Table 1 summarizes the cytotoxicity of glaziiovianin A (**1**) and its analogues against HeLa S₃ cells and their calculated Log P (cLog P) values.¹⁴ Compound **12**, which has an acetonide group instead of the methylene acetal group of glaziiovianin A (**1**), showed no cytotoxicity even at 100 μ M. Also, compound **13**, which has methoxy groups at C3' and C4' instead of the methylene acetal group, was much less cytotoxic than glaziiovianin A (**1**). These results indicated that the steric hindrance of C3' and C4' at the B-ring part reduced the cytotoxicity of glaziiovianin A (**1**) to a large extent. Compound **14**, which lacks methoxy groups at C2' and C5', was about 100-fold less cytotoxic than glaziiovianin A (**1**). Also, compound **15**, which has a bromo group at C6' of the B-ring, was less cytotoxic than glaziiovianin A (**1**). These results suggested that the electron density and/or steric hindrance of the B-ring might be responsible for cytotoxicity. On the other hand, compound **21**, which has an extra methoxy group at C5 of the A-ring, showed no cytotoxicity even at 100 μ M, indicating that the steric hindrance and electron density of the A-ring extinguished cytotoxicity. *O*⁷-Demethyl analogue **22** exhibited no cytotoxicity, perhaps because of its instability. On the other hand, compounds **24**, **25**, and **27**, which have *O*⁷-hydrophilic functional groups, showed no cytotoxicity at 100 μ M, and the cLog P values of these compounds, 1.00, 0.08, and 1.13, are much smaller than that of glaziiovianin A (**1**). These results showed that the improvement of water solubility diminishes cytotoxicity. In contrast, compounds **26**, **28**, and **29**, which have, respectively, an allyl, a benzyl, and a propargyl group at *O*⁷ instead of the methyl group, showed cytotoxicity with IC₅₀ values of 0.46, 0.19, and 0.17 μ M, respectively.¹⁵ Thus, some alkyl groups at *O*⁷ had enhanced cytotoxicity against HeLa S₃ cells. In particular, *O*⁷-propargyl analogue **29** is more active than glaziiovianin A (**1**) itself. These results indicated that the hydrophobicity of the *O*⁷-alkyl group in glaziiovianin A analogues improves cytotoxicity. However, compound **20**, which has a THP group at *O*⁷, showed no cytotoxicity even at 100 μ M. This indicated that steric hindrance of the *O*⁷-substituent reduces cytotoxicity to a large extent.

Table 1 Cytotoxicity of glaziovianin A (**1**) and its analogues against HeLa S₃ cells

compound	cLog P	cytotoxicity	
		IC ₅₀ (μM)	relative value
glaziovianin A (1)	2.19	0.59	1
12	2.79	>100	-
13	2.15	22.0	0.027
14	2.44	56.2	0.010
15	3.02	67.8	0.009
20	3.03	>100	-
21	2.06	>100	-
22	1.92	>100	-
24	1.00	>100	-
25	0.08	>100	-
26	2.88	0.46	1.3
27	1.13	>100	-
28	3.92	0.19	3.1
29	2.40	0.17	3.5

and spindle structures.^{16,17} As shown in Figures 3A–E, all the analogues inhibited the cell cycle progression in the G₂/M phase at a concentration of 1 μM for 24 h treatment. To confirm whether or not these compounds also induce abnormal spindle structures with unaligned chromosomes, as does **1**, microtubules and chromosomes in mitotic cells treated with 1 μM *O*⁷-alkylated analogues for 6 h were observed (Figures 3F–J). Normal bipolar spindles were observed in DMSO-treated cells, but abnormal multipolar spindles were formed in most of the cells treated with **1** (Figures 3F and 3G, respectively). As expected, analogues **26**, **28**, and **29** also induced abnormal multipolar spindles, and these structures were resembled with the spindles induced by **1** (Figures 3H–J). Because it is well known that the disruption of a mitotic spindle inhibits mitosis by activating the spindle checkpoint, these results strongly suggested that *O*⁷-alkylated analogues inhibited cell cycle progression in the M phase by inducing abnormal spindle formation. Especially, benzyl (**28**) and propargyl (**29**) analogues completely arrested cell cycle progression, indicating that these compounds are more potent cell cycle inhibitors than **1** and **26**.

2.4. Effects of glaziovianin A (**1**) and *O*⁷-alkylated analogues **26**, **28**, and **29** on cell cycle progression and spindle structures in HeLa S₃ cells

We previously reported that glaziovianin A (**1**) inhibited the cell cycle progression in the M-phase with abnormal spindle structures.¹ Here, we investigated the effects of the cytotoxic *O*⁷-alkylated analogues **26**, **28**, and **29** on both cell cycle progression





Figure 3. Effects of glaziovianin A (**1**) and *O*⁷-alkylated analogues **26**, **28**, and **29** on cell cycle progression and spindle structures in HeLa S₃ cells.

(A–E) *O*⁷-alkylated analogues inhibited cell cycle progression in G₂/M phase. HeLa S₃ cells were treated with DMSO (A), 1 μM of glaziovianin A (**1**) (B), compound **26** (C), **28** (D), or **29** (E) for 24 h, and DNA contents were determined with flow cytometric analysis.

(F–J) *O*⁷-alkylated analogues induced abnormal spindle formation. HeLa S₃ cells were treated with DMSO (F), 1 μM of glaziovianin A (**1**) (G), compound **26** (H), **28** (I), or **29** (J) for 6 h, and microtubules (green) and chromosomes (blue) were stained with anti- α -tubulin antibody (DM1A, Santa Cruz Biotechnology) and DAPI, respectively.

2.5 Synthesis of biotin, fluorescence, and photoaffinity probes of glaziovianin A


In section 2.3, we described that O^7 -alkylated glaziovianin A analogues showed more potent cytotoxicity against HeLa S₃ cells than glaziovianin A itself. So, we next examined the synthesis of O^7 -modified molecular probes of glaziovianin A for biological studies and target identification. First, we synthesized a biotin probe of glaziovianin A (**1**) to confirm the target biomolecule, tubulin (Scheme 5). Condensation of mono-Boc-1,6-diaminohexane **30**¹⁸ with 6-benzyloxyhexanoic acid **31**¹⁹ gave amide **32**. Removal of the benzyl group of **32** afforded an alcohol, which was converted into bromide **33**. The coupling reaction between bromide **33** and O^7 -demethyl analogue **22**, followed by removal of the Boc group gave amine **34** as a TFA salt. Amidation of amine **34** with (+)-biotin *N*-hydroxysuccinimide ester **35**²⁰ afforded O^7 -biotinyl glaziovianin A (**36**).



Scheme 5. Synthesis of biotin probe of glaziovianin A. Reagents and conditions: (a) DCC, HOBT, DMF, rt, 81%; (b) H₂, 5% Pd/C, EtOH, rt, 89%; (c) NBS, PPh₃, CH₂Cl₂, rt, 40%; (d) **22**, K₂CO₃, MeCN, reflux, 34%, recovery of **22**: 46%; (e) TFA, CH₂Cl₂, rt, 62%; (f) **35**, Et₃N, DMF, rt, 41%.

Next, we synthesized a fluorescent probe for a dynamic analysis of glaziovianin A in living cells, as well as a photoaffinity probe for an analysis of the binding site between glaziovianin A and the target protein. In Scheme 5, the coupling reaction between bromide **33** and O^7 -demethyl analogue **22** was in low yield, perhaps because of the low reactivity of bromide **33**. Therefore, we next tried to employ allylic bromide **42** as a linker (Scheme 6). Reduction of known aldehyde **37**²¹ gave allylic alcohol **38**, which was protected by a TBS group, thus affording TBS ether **39**. Condensation of TBS ether **39** and amine **30** gave amide **40**. Removal of the TBS group in **40** afforded allylic alcohol **41**, which was converted into allylic bromide **42**. The coupling reaction between O^7 -demethyl analogue **22** and allylic bromide **42** gave the coupling compound **43** in good (72%) yield. Removal of the Boc group in coupling compound **43** gave amine **44** as a TFA salt. Amidation of compound **44** with *N*-hydroxysuccinimide esters, such as (+)-biotin analogue **35**,²⁰ trifluoromethyldiazirine analogue **48**,²² and BODIPY analogue

49,²³ afforded O^7 -modified biotin probe **45**, photoaffinity probe **46**, and fluorescent probe **47**, respectively.



Scheme 6. Synthesis of biotin, photoaffinity, and fluorescent probes of glaziovianin A. Reagents and conditions: (a) NaBH₄, MeOH, 0 °C, 70%; (b) TBSCl, imidazole, DMF, rt, 91%; (c) **30**, toluene, reflux, 69%; (d) TBAF, THF, rt, 86%; (e) NBS, PPh₃, CH₂Cl₂, rt, 64%; (f) **22**, K₂CO₃, MeCN, reflux, 72%, recovery of **22**: 14%; (g) TFA, CH₂Cl₂, rt, 55%; (h) **35**, Et₃N, DMF, rt, 47% (i) **48**, Et₃N, MeCN, rt, 49%; (j) **49**, Et₃N, DMF, rt, 65%.

The cytotoxicities of biotin probes **36** and **45**, as well as that of fluorescent probe **47**, against HeLa S₃ cells are shown in Table 2. Each of these probes was about 30-fold less cytotoxic than glaziovianin A (**1**). However, they all maintained sufficient cytotoxicities to be used as probes.

Table 2 Cytotoxicities of glaziovianin A (**1**) and the molecular probes of glaziovianin A against HeLa S₃ cells

compound	cytotoxicity	
	IC ₅₀ (μM)	relative value
glaziovianin A (1)	0.59	1
biotin probe 36	15.2	0.039
biotin probe 45	15.5	0.038
BODIPY probe 47	17.4	0.034

3. Conclusion

In conclusion, we have investigated the structure–cytotoxicity relationships of glaziovianin A (**1**). The results revealed that *O*⁷-modified glaziovianin A analogues have strong cytotoxicity against HeLa S₃ cells. Among them, *O*⁷-benzyl and *O*⁷-propargyl analogues **28** and **29** completely arrested cell cycle progression, indicating that these compounds are more potent cell cycle inhibitors than glaziovianin A (**1**). Furthermore, we have synthesized *O*⁷-modified molecular probes of glaziovianin A for biological studies. Further searches for target biomolecules of glaziovianin A (**1**) by using these probes are in progress.

4. Experimental section

4.1. Chemistry

General method

¹H NMR spectra were recorded on a JEOL JNM-EX270 (270 MHz) or a Bruker AVANCE 500 (500 MHz) spectrometer. Chemical shifts for ¹H NMR are reported in parts per million (ppm) downfield from tetramethylsilane as the internal standard, and coupling constants are in hertz (Hz). The following abbreviations are used for spin multiplicity: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, and br = broad. ¹³C NMR spectra were recorded on a JEOL JNM-EX270 (67.8 MHz) or a Bruker AVANCE 500 (125 MHz) spectrometer. Chemical shifts for ¹³C NMR are reported in ppm, relative to the central line of a triplet at 77.0 ppm for deuteriochloroform. IR spectra were recorded on a JASCO FT/IR-300 instrument and are reported in wavenumbers (cm⁻¹). High resolution ESI mass spectra were recorded on an Applied Biosystems QStar/Pulsar *i* spectrometer. Fuji Silysia silica gel BW-820MH was used for column chromatography. Anhydrous benzene, CH₂Cl₂, MeOH, THF, toluene, and MeCN were used as obtained from commercial supplies for moisture-sensitive reaction. Other organic solvents for moisture-sensitive reactions were distilled by standard procedure. MS3A was heated in a microwave oven for 2 minutes.

4.1.1. 4,7-Dimethoxy-2,2-dimethylbenzo[d][1,3]dioxole (**7**)

To a stirred solution of catechol **6** (54.3 mg, 319 μmol) in benzene (2.5 mL) were added PPTS (5.5 mg, 21.9 μmol) and 2-methoxypropene (0.10 mL, 1.04 mmol) at room temperature. After being stirred at reflux for 48 h, the mixture was cooled to room temperature, diluted with EtOAc (5 mL), and washed with 1 M aqueous NaOH (3 mL). The EtOAc solution was washed with brine (3 mL), dried (Na₂SO₄), and concentrated. The residual solid was purified by column chromatography on silica

gel (0.8 g, hexane–EtOAc = 40:1) to give acetone **7** (48.6 mg, 72%) as a white solid: IR (CHCl₃) 3024, 2987, 2941, 1612, 1450, 1423, 1055 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 6.40 (s, 2H), 3.84 (s, 6H), 1.73 (s, 6H); ¹³C NMR (67.8 MHz, CDCl₃) δ 120.5 (2C), 118.6 (2C), 117.0 (2C), 106.5, 60.1 (2C), 20.9 (2C); HRMS (ESI) *m/z* 233.0772, calcd for C₁₁H₁₄NaO₄ [M+Na]⁺ 233.0784.

4.1.2. 5-Bromo-4,7-dimethoxy-2,2-dimethylbenzo[d][1,3]dioxole (**7a**)

To a stirred solution of acetone **7** (48.6 mg, 231 μmol) in DMF (2.6 mL) was added NBS (34.9 mg, 196 μmol) at 0 °C. After being stirred at room temperature for 18 h in dark, the mixture was diluted with water (3 mL) and extracted with CH₂Cl₂ (2 mL×3). The combined extracts were washed with brine (5 mL), dried (Na₂SO₄), and concentrated. The residual solid was purified by column chromatography on silica gel (2.0 g, hexane–CH₂Cl₂ = 8:1) to give bromide **7a** (38.2 mg, 57%) as a white solid: IR (CHCl₃) 3007, 2992, 2941, 1610, 1453, 1430, 1412, 1045, 1026 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 6.64 (s, 1H), 3.89 (s, 3H), 3.83 (s, 3H), 1.72 (s, 6H); ¹³C NMR (67.8 MHz, CDCl₃) δ 131.2, 130.7, 128.1, 126.9, 126.4, 115.2, 105.8, 61.5, 59.7, 21.3, 21.2; HRMS (ESI) *m/z* 310.9899, calcd for C₁₁H₁₃BrNaO₄ [M+Na]⁺ 310.9889.

4.1.3. 2-(4,7-Dimethoxy-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (**8**)

To a stirred solution of bis(pinacolato)diboron (52.5 mg, 207 μmol), PdCl₂(dppf)·CH₂Cl₂ (11.3 mg, 13.8 μmol), and KOAc (54.5 mg, 556 μmol) in DMF (0.60 mL) was added a solution of bromide **7a** (39.7 mg, 138 μmol) in DMF (0.50 mL) at room temperature. After being stirred at 150 °C under a stream of N₂ for 3 h, the mixture was cooled to room temperature, diluted with EtOAc (4 mL), and washed with brine (2 mL). The EtOAc solution was dried (Na₂SO₄), filtered through a pad of Florisil, and concentrated. The residual oil was purified by column chromatography on silica gel (0.8 g, hexane–EtOAc = 100:1 → 20:1) to give arylboronate **8** (12.9 mg, 28%) as a white solid: IR (CHCl₃) 3010, 2987, 2941, 1608, 1452, 1435, 1302, 1058 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 6.81 (s, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 1.70 (s, 6H), 1.33 (s, 12H); ¹³C NMR (67.8 MHz, CDCl₃) δ 142.9, 142.5, 139.1, 138.8, 137.7, 114.0, 106.6, 83.1 (2C), 61.4, 57.2, 25.0 (4C), 21.6, 21.4; HRMS (ESI) *m/z* 359.1646, calcd for C₁₇H₂₅BNaO₆ [M+Na]⁺ 359.1636.

4.1.4. 3-(4,7-Dimethoxy-2,2-dimethylbenzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-4H-chromen-4-one (**12**)

All solvents were degassed by freeze–thawing. To a stirred solution of arylboronate **8** (12.9 mg, 38.4 μmol) and PdCl₂(dppf)·CH₂Cl₂ (3.1 mg, 3.79 μmol) in 1,4-dioxane (0.25 mL) were added aqueous 1 M Na₂CO₃ (0.19 mL, 190 μmol) and iodochromone **3** (19.1 mg, 57.5 μmol) in 1,4-dioxane (0.30 mL) at room temperature. After being stirred at room temperature under a stream of N₂ for 36 h, the mixture was diluted with EtOAc (2 mL) and filtered through a pad of Florisil. The filtrate was washed with brine (4 mL), dried (Na₂SO₄), and concentrated. The residual solid was purified by column chromatography on silica gel (0.6 g, hexane–EtOAc = 10:1 → 1:1) to give a brown solid (containing Pd-metal) (10.1 mg, 64%). The brown solid (10.1 mg) was dissolved in CHCl₃ (1 mL), and SiliaBond (SILICYCLE, SiliaBond Thiourea, 100 mg) was added. The

resulting mixture was stirred at room temperature for 30 min, filtered, and concentrated to give glaziovianin A analogue **12** (10.1 mg, 64%) as a white solid: IR (CHCl₃) 3016, 2937, 1634, 1605, 1444, 1278, 1160, 1037 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 7.92 (s, 1H), 7.62 (s, 1H), 6.87 (s, 1H), 6.49 (s, 1H), 3.99 (s, 3H), 3.98 (s, 3H), 3.88 (s, 3H), 3.85 (s, 3H), 1.67 (s, 3H), 1.65 (s, 3H); ¹³C NMR (67.8 MHz, CDCl₃) δ 175.5, 154.0, 153.2, 152.1, 147.4, 139.0, 138.5, 137.0, 136.5, 121.5, 117.9, 117.7, 110.3, 106.4, 104.7, 99.4, 60.2, 56.9, 56.2, 56.0, 20.9, 20.7; HRMS (ESI) *m/z* 437.1213, calcd for C₂₂H₂₂NaO₈ [M+Na]⁺ 437.1207.

4.1.5. 2,3,4,5-Tetramethoxyphenylboronic acid (**10**)

To a stirred solution of tetramethoxybenzene **9** (101 mg, 510 μmol) in THF (1.0 mL) was added *n*-BuLi (1.63 M solution in hexane, 0.34 mL, 554 μmol) slowly at room temperature. After the mixture was stirred at room temperature for 15 min, B(OMe)₃ (0.34 mL, 2.99 mmol) was added into the mixture at -78 °C. The reaction mixture was stirred at room temperature for 3 h, diluted with aqueous 1 M HCl (2.5 mL), stirred at room temperature for 3 h, and extracted with ether (2 mL×3). The combined extracts were washed with brine (5 mL) and dried (MgSO₄). Removal of the solvent afforded boronic acid **10** (138 mg) as a white solid, which was used for the next reaction without further purification.

4.1.6. 6,7-Dimethoxy-3-(2,3,4,5-tetramethoxyphenyl)-4H-chromen-4-one (**13**)

To a stirred solution of crude boronic acid **10** (41.0 mg, 152 μmol) and PdCl₂(dppf)·CH₂Cl₂ (17.8 mg, 15.4 μmol) in 1,4-dioxane (1.0 mL) were added 1 M Na₂CO₃ aq. (0.75 mL, 750 μmol) and iodochromone **3** (103 mg, 310 μmol) in 1,4-dioxane (1.0 mL) at room temperature. After being stirred at room temperature under a stream of N₂ for 17 h, the reaction mixture was diluted with water (1 mL) and extracted with CH₂Cl₂ (2 mL×3). The combined extracts were washed with brine (3 mL), dried (Na₂SO₄), filtered through a pad of Florisil, and concentrated. The residual oil was purified by column chromatography on silica gel (3.0 g, hexane-EtOAc = 4:1 → 2:1) to give a brown solid (containing Pd-metal) (7.0 mg). The brown solid (7.0 mg) was dissolved in CHCl₃ (1 mL), and SiliaBond (SILICYCLE, SiliaBond Thiourea, 70 mg) was added. The resulting mixture was stirred at room temperature for 30 min, filtered, and concentrated to give glaziovianin A analogue **13** (7.0 mg, 11% in 2 steps) as a white solid: IR (CHCl₃) 3010, 2946, 1637, 1606, 1448, 1297, 1271, 1072 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 7.92 (s, 1H), 7.62 (s, 1H), 6.88 (s, 1H), 6.67 (s, 1H), 4.00 (s, 3H), 3.98 (s, 3H), 3.93 (s, 3H), 3.91 (s, 3H), 3.87 (s, 3H), 3.86 (s, 3H); ¹³C NMR (67.8 MHz, CDCl₃) δ 175.0, 154.4, 153.3, 152.0, 147.4, 139.9, 139.3, 137.8, 137.4, 121.5, 119.0, 117.7, 110.6, 104.8, 99.7, 60.8, 58.7, 57.4, 57.1, 56.4, 56.2; HRMS (ESI) *m/z* 425.1201, calcd for C₂₁H₂₂NaO₈ [M+Na]⁺ 425.1207.

4.1.7. 3-(Benzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-4H-chromen-4-one (**14**)

To a stirred solution of boronic acid **11** (50.4 mg, 152 μmol) and PdCl₂(dppf)·CH₂Cl₂ (17.1 mg, 14.8 μmol) in 1,4-dioxane (1.0 mL) were added 1 M Na₂CO₃ aq. (0.75 mL, 750 μmol) and iodochromone **3** (108 mg, 323 μmol) in 1,4-dioxane (1.0 mL) at room temperature. After being stirred at room temperature under a stream of N₂ for 12 h, the reaction mixture was diluted with water (1 mL) and extracted with CH₂Cl₂ (2 mL×3). The

combined extracts were washed with brine (3 mL), dried (Na₂SO₄), filtered through a pad of Florisil, and concentrated. The residual oil was purified by column chromatography on silica gel (0.7 g, hexane-CHCl₃ = 1:1 → 1:2) to give a brown solid (containing Pd-metal) (21.0 mg). The brown solid (21.0 mg) was dissolved in CHCl₃ (3 mL), and SiliaBond (SILICYCLE, SiliaBond Thiourea, 200 mg) was added. The resulting mixture was stirred at room temperature for 30 min, filtered, and concentrated to give a glaziovianin A analogue **14** (20.2 mg, 41%) as a white solid: IR (CHCl₃) 3005, 2940, 1635, 1608, 1439, 1274, 1154 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 7.92 (s, 1H), 7.62 (s, 1H), 7.11 (d, *J* = 1.9 Hz, 1H), 6.98 (dd, *J* = 8.1, 1.9 Hz, 1H), 6.88 (s, 1H), 6.87 (d, *J* = 8.1 Hz, 1H), 5.99 (s, 2H), 3.99 (s, 3H), 3.99 (s, 3H); ¹³C NMR (67.8 MHz, CDCl₃) δ 175.2, 154.1, 153.1, 152.2, 147.6, 143.0, 142.2, 139.9, 139.0, 121.8, 121.6, 117.6, 113.8, 104.9, 101.8, 99.7, 56.5, 56.3; HRMS (ESI) *m/z* 349.0683, calcd for C₁₈H₁₄NaO₆ [M+Na]⁺ 349.0683.

4.1.8. 3-(6-Bromo-4,7-dimethoxybenzo[d][1,3]dioxol-5-yl)-6,7-dimethoxy-4H-chromen-4-one (**15**)

To a stirred solution of glaziovianin A (**1**) (10.2 mg, 26.4 μmol) in DMF (0.25 mL) was added NBS (4.7 mg, 26.6 μmol) at room temperature. After being stirred at room temperature for 6 h, the reaction mixture was diluted with water (0.5 mL) and extracted with CH₂Cl₂ (1 mL×3). The combined extracts were washed with brine (2 mL), dried (Na₂SO₄), and concentrated. The residual oil was purified by column chromatography on silica gel (0.7 g, hexane-EtOAc = 5:1 → 2:1) to give a bromide **15** (3.8 mg, 31%) as a white solid: IR (CHCl₃) 3004, 2937, 1640, 1612, 1505, 1428, 1264, 1155, 1047 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 7.75 (s, 1H), 7.62 (s, 1H), 6.92 (s, 1H), 6.03 (s, 2H), 4.00 (s, 3H), 3.99 (s, 3H), 3.85 (s, 3H), 3.83 (s, 3H); ¹³C NMR (67.8 MHz, CDCl₃) δ 175.2, 154.2, 153.3, 152.0, 147.2, 139.1, 138.7, 137.2, 136.5, 121.6, 118.3, 117.6, 104.9, 101.8, 99.5, 86.4, 60.5, 57.2, 56.4, 56.2; HRMS (ESI) *m/z* 486.9985, calcd for C₂₀H₁₇BrNaO₈ [M+Na]⁺ 486.9999.

4.1.9. 1-(2-Hydroxy-5-methoxy-4-(tetrahydro-2H-pyran-2-yloxy)phenyl)ethanone (**17**)

To a stirred solution of phenol **16** (16.5 mg, 90.7 μmol) in CH₂Cl₂ (0.90 mL) were added DHP (102 μL, 1.12 μmol) and PPTS (3.2 mg, 12.7 μmol) at 0 °C. After being stirred at room temperature for 18 h, the reaction mixture was diluted with saturated aqueous NaHCO₃ (1 mL) and extracted with CH₂Cl₂ (2 mL×3). The combined extracts were washed with brine (2 mL), dried (Na₂SO₄), and concentrated. The residual solid was purified by column chromatography on silica gel (1.5 g, hexane-EtOAc = 20:1) to give THP ether **17** (19.3 mg, 80%) as a white solid: IR (CHCl₃) 3518, 3014, 2950, 1632, 1504, 1372, 1330, 1261, 1228, 1216, 1208 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 12.5 (s, 1H), 7.12 (s, 1H), 6.74 (s, 1H), 5.50 (t, *J* = 3.0 Hz, 1H), 3.89–3.82 (m, 1H), 3.85 (s, 3H), 3.66–3.62 (m, 1H), 2.56 (s, 3H), 2.01–1.89 (m, 3H), 1.74–1.64 (m, 3H); ¹³C NMR (67.8 MHz, CDCl₃) δ 201.8, 159.3, 154.2, 142.1, 113.3, 112.3, 104.3, 96.6, 62.1, 57.1, 29.9, 26.2, 24.8, 18.5; HRMS (ESI) *m/z* 289.1051, calcd for C₁₄H₁₈NaO₅ [M+Na]⁺ 289.1046.

4.1.10. (E)-3-(Dimethylamino)-1-(2-hydroxy-5-methoxy-4-(tetrahydro-2H-pyran-2-yloxy)phenyl)prop-2-en-1-one (17a)

THP ether **17** (19.3 mg, 72.6 μmol) was dissolved in *N,N*-dimethylformamide dimethyl acetal (0.10 mL, 754 μmol). The reaction mixture was stirred at 90 °C for 12 h and concentrated to afford enamine **17a** (23.3 mg, quant.) as a yellow solid. Enamine **17a** was used for next reaction without further purification: IR (CHCl_3) 3689, 2949, 1631, 1541, 1507, 1372, 1284, 1222, 1209, 1108 cm^{-1} ; ^1H NMR (270 MHz, CDCl_3) δ 14.0 (s, 1H), 7.84 (d, $J = 12.4$ Hz, 1H), 7.18 (s, 1H), 6.72 (s, 1H), 5.62 (d, $J = 12.4$ Hz, 1H), 5.46 (t, $J = 3.2$ Hz, 1H), 3.89 (m, 1H), 3.85 (s, 3H), 3.63 (m, 1H), 3.22 (br s, 3H), 3.17 (br s, 3H), 2.01–1.88 (m, 3H), 1.72–1.61 (m, 3H); ^{13}C NMR (67.8 MHz, CDCl_3) δ 190.2, 160.0, 154.0, 152.7, 141.7, 113.6, 112.9, 105.0, 96.8, 89.8, 62.4, 58.2, 40.3 (2C), 30.2, 25.1, 19.0; HRMS (ESI) m/z 344.1471, calcd for $\text{C}_{17}\text{H}_{23}\text{NNaO}_5$ $[\text{M}+\text{Na}]^+$ 344.1474.

4.1.11. 3-Iodo-6-methoxy-7-(tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one (18)

To a stirred solution of enamine **17a** (150 mg, 467 μmol) in CHCl_3 (4.7 mL) were added pyridine (0.19 mL, 2.36 mmol) and I_2 (250 mg, 984 μmol) at 0 °C. After being stirred at room temperature for 12 h in dark, the mixture was diluted with saturated aqueous $\text{Na}_2\text{S}_2\text{O}_3$ (5 mL), stirred at room temperature for 10 min, and extracted with EtOAc (5 mL \times 3). The combined extracts were washed with brine (10 mL), dried (Na_2SO_4), and concentrated. The residual solid was purified by column chromatography on silica gel (8 g, hexane–EtOAc = 10:1 \rightarrow 4:1) to give iodochromone **18** (140 mg, 75%) as a white solid: IR (CHCl_3) 3024, 2999, 1640, 1605, 1541, 1503, 1350, 1219, 1203 cm^{-1} ; ^1H NMR (270 MHz, CDCl_3) δ 8.22 (s, 1H), 7.55 (s, 1H), 7.20 (s, 1H), 5.55 (t, $J = 2.7$ Hz, 1H), 3.95 (s, 3H), 3.91–3.82 (m, 1H), 3.68–3.63 (m, 1H), 2.10–1.87 (m, 3H), 1.77–1.62 (m, 3H); ^{13}C NMR (67.8 MHz, CDCl_3) δ 172.2, 156.8, 156.7, 151.7, 148.5, 115.6, 105.2, 103.7, 97.1, 86.2, 62.0, 56.3, 29.9, 24.9, 18.3; HRMS (ESI) m/z 424.9867, calcd for $\text{C}_{15}\text{H}_{15}\text{INaO}_5$ $[\text{M}+\text{Na}]^+$ 424.9862.

4.1.12. 3-(4,7-Dimethoxybenzo[*d*][1,3]dioxol-5-yl)-6-methoxy-7-(tetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one (20)

All solvents were degassed by freeze–thawing. To a stirred solution of arylboronate **5** (10.1 mg, 32.8 μmol) and $\text{PdCl}_2(\text{dppf})\cdot\text{CH}_2\text{Cl}_2$ (2.2 mg, 2.69 μmol) in 1,4-dioxane (0.10 mL) were added aqueous 1 M Na_2CO_3 (0.13 mL) and iodochromone **18** (10.4 mg, 25.9 μmol) in 1,4-dioxane (0.22 mL) at room temperature. After being stirred at room temperature under a stream of N_2 for 24 h, the reaction mixture was diluted with water (1 mL) and extracted with CH_2Cl_2 (1 mL \times 3). The combined extracts were washed with brine (2 mL), dried (Na_2SO_4), filtered through a pad of Florisil, and concentrated. The residual oil was purified by column chromatography on silica gel (0.7 g, hexane–EtOAc = 4:1 \rightarrow 2:1) to give a brown oil (7.9 mg). The brown oil (7.9 mg) was dissolved in CHCl_3 (1 mL), and SiliaBond (SILICYCLE, SiliaBond Thiourea, 80 mg) was added. The resulting mixture was stirred at room temperature for 30 min, filtered, and concentrated to give a glaziovianin A analogue **20** (7.8 mg, 66%) as a white solid: IR (CHCl_3) 3007, 2948, 1639, 1607, 1500, 1468, 1430, 1352, 1297 cm^{-1} ; ^1H NMR (270 MHz, CDCl_3) δ 7.90 (s, 1H), 7.62 (s, 1H), 7.22 (s, 1H), 6.52 (s, 1H), 6.01 (s, 2H), 5.56 (s, 1H), 3.96 (s, 3H), 3.86 (s, 3H), 3.83 (s, 3H), 2.06–1.97 (m, 4H), 1.72–1.68 (m, 4H); ^{13}C NMR (67.8 MHz, CDCl_3) δ 175.4, 153.5, 151.8, 151.4, 148.2, 139.0, 138.8,

136.9, 136.6, 121.3, 118.4, 118.0, 109.9, 105.3, 104.2, 101.9, 97.1, 62.1, 60.2, 56.9, 56.4, 30.1, 25.1, 18.5; HRMS (ESI) m/z 479.1310, calcd for $\text{C}_{24}\text{H}_{24}\text{NaO}_9$ $[\text{M}+\text{Na}]^+$ 479.1313.

4.1.13. 3-(4,7-Dimethoxybenzo[*d*][1,3]dioxol-5-yl)-5,6,7-trimethoxy-4H-chromen-4-one (21)

All solvents were degassed by freeze–thawing. To a stirred solution of arylboronate **5** (20.6 mg, 66.9 μmol) and $\text{PdCl}_2(\text{dppf})\cdot\text{CH}_2\text{Cl}_2$ (5.8 mg, 7.10 μmol) in 1,4-dioxane (0.45 mL) were added aqueous 1 M Na_2CO_3 (0.32 mL, 320 μmol) and iodochromone **19** (36.5 mg, 101 μmol) in 1,4-dioxane (0.48 mL) at room temperature. After being stirred at room temperature under a stream of N_2 for 48 h, the reaction mixture was diluted with EtOAc (2 mL) and filtered through a pad of Florisil. The filtrate was washed with brine (4 mL), dried (Na_2SO_4), and concentrated. The residual solid was purified by column chromatography on silica gel (1.5 g, hexane–EtOAc = 5:1 \rightarrow 2:1) to give glaziovianin A analogue **21** (4.5 mg, 16%) as a white solid: IR (CHCl_3) 3013, 2998, 2933, 1646, 1611, 1508, 1428, 1231, 1157, 1068 cm^{-1} ; ^1H NMR (270 MHz, CDCl_3) δ 7.88 (s, 1H), 6.71 (s, 1H), 6.52 (s, 1H), 6.01 (s, 2H), 3.96 (s, 3H), 3.95 (s, 3H), 3.92 (s, 3H), 3.86 (s, 3H), 3.85 (s, 3H); ^{13}C NMR (67.8 MHz, CDCl_3) δ 175.2, 154.7, 153.3, 151.6, 148.9, 142.8, 139.0, 138.7, 136.9, 136.6, 121.4, 117.9, 113.1, 109.8, 101.7, 92.5, 60.3, 56.9, 56.6, 56.4, 56.3; HRMS (ESI) m/z 439.0999, calcd for $\text{C}_{21}\text{H}_{20}\text{NaO}_9$ $[\text{M}+\text{Na}]^+$ 439.1000.

4.1.14. 3-(4,7-Dimethoxybenzo[*d*][1,3]dioxol-5-yl)-7-hydroxy-6-methoxy-4H-chromen-4-one (22)

To a stirred solution of glaziovianin A analogue **20** (24.0 mg, 52.6 μmol) in CHCl_3 (0.50 mL) and MeOH (0.10 mL) was added *p*-TsOH \cdot H $_2$ O (1.1 mg, 5.79 μmol) at room temperature. After the mixture was stirred at room temperature for 3 h, Et_3N (0.01 mL) was added. Removal of solvent gave a solid, which was purified by column chromatography on silica gel (0.6 g, hexane–EtOAc = 1:1 \rightarrow 1:3) to give *O*⁷-demethyl analogue **22** (16.7 mg, 85%) as a white solid: IR (CHCl_3) 3610, 3015, 2945, 1635, 1599, 1502, 1461, 1288 cm^{-1} ; ^1H NMR (270 MHz, CDCl_3) δ 7.89 (s, 1H), 7.64 (s, 1H), 6.98 (s, 1H), 6.52 (s, 1H), 6.02 (s, 2H), 4.02 (s, 3H), 3.87 (s, 3H), 3.85 (s, 3H), (OH proton was not observed); ^{13}C NMR (67.8 MHz, CDCl_3) δ 175.3, 153.8, 151.6, 151.8, 148.2, 139.1, 138.8, 137.1, 136.6, 121.2, 118.5, 117.6, 109.7, 105.3, 104.0, 102.0, 60.1, 56.9, 56.6; HRMS (ESI) m/z 395.0745, calcd for $\text{C}_{19}\text{H}_{16}\text{NaO}_8$ $[\text{M}+\text{Na}]^+$ 395.0737.

4.1.15. (3*R*,4*S*,5*R*)-2-(Acetoxymethyl)-6-(3-(4,7-dimethoxybenzo[*d*][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4H-chromen-7-yloxy)tetrahydro-2H-pyran-3,4,5-triyl triacetate (24)

To a stirred solution of *O*⁷-demethyl analogue **22** (24.7 mg, 66.4 μmol) and MS3A (244 mg) in CH_2Cl_2 (0.50 mL) were added a solution of imidate **23** (65.1 mg, 133 μmol) in CH_2Cl_2 (0.50 mL) and $\text{BF}_3\cdot\text{Et}_2\text{O}$ (0.03 mL, 243 μmol) at 0 °C. After being stirred at room temperature for 12 h, the mixture was diluted with water (2 mL) and extracted with CH_2Cl_2 (2 mL \times 3). The combined extracts were washed with brine (5 mL), dried (Na_2SO_4), and concentrated. The residual solid was purified by column chromatography on silica gel (0.7 g, hexane–EtOAc = 4:1 \rightarrow 2:1) to give tetraacetyl glycosylisoflavone **24** (mixture of anomeric isomers, α -isomer: 1.9 mg, 4.1%; β -isomer: 10.7 mg,

23%) as white solids: **24** (β -isomer): IR (CHCl₃) 3009, 2940, 1672, 1667, 1646, 1522, 1434, 1245 cm⁻¹; ¹H NMR (270 MHz, pyridine-*d*₅) δ 8.19 (s, 1H), 7.84 (s, 1H), 7.57 (s, 1H), 6.77 (s, 1H), 5.99 (s, 2H), 5.92 (d, *J* = 8.4 Hz, 1H), 4.67–4.45 (m, 6H), 4.00 (s, 3H), 3.80 (s, 3H), 3.70 (s, 3H), 2.11 (s, 3H), 2.10 (s, 3H), 2.05 (s, 3H), 2.04 (s, 3H); ¹³C NMR (67.8 MHz, pyridine-*d*₅) δ 173.8, 170.9, 170.4, 169.8, 169.3, 157.8, 153.9, 151.8, 151.4, 140.0, 138.9, 137.8, 136.7, 126.5, 120.7, 118.9, 109.4, 107.1, 106.9, 103.4, 101.5, 72.9, 71.8, 71.3, 68.5, 64.2, 62.0, 58.4, 58.2, 21.8, 21.3, 20.8, 20.5; HRMS (ESI) *m/z* 725.1694, calcd for C₃₃H₃₄NaO₁₇ [M+Na]⁺ 725.1688.

4.1.16. 3-(4,7-Dimethoxybenzo[*d*][1,3]dioxol-5-yl)-6-methoxy-7-((3*R*,4*S*,5*S*)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2*H*-pyran-2-yloxy)-4*H*-chromen-4-one (25)

To a stirred solution of tetraacetyl glycosylisoflavone **24** (mixture of anomeric isomers, 4.5 mg, 6.41 μ mol) in MeOH (0.09 mL) was added NaOMe (3.5 mg, 69.4 μ mol) at 0 °C. After being stirred at room temperature for 1 h, the mixture was diluted with water (1 mL) and extracted with CHCl₃ (1 mL \times 6). The combined extracts were dried (Na₂SO₄) and concentrated to give mixture of glycoside **25** (α -isomer: 0.4 mg, 12%; β -isomer 2.7 mg, 79%) as white solids: **25** (β -isomer): IR (CHCl₃) 3540, 3015, 2944, 1646, 1530, 1456, 1435, 1246 cm⁻¹; ¹H NMR (270 MHz, pyridine-*d*₅) δ 8.07 (s, 1H), 7.86 (s, 1H), 7.64 (s, 1H), 6.74 (s, 1H), 5.99 (s, 2H), 5.89 (d, *J* = 7.0 Hz, 1H), 4.67–4.61 (m, 1H), 4.44–4.26 (m, 5H), 3.99 (s, 3H), 3.79 (s, 3H), 3.63 (s, 3H), (Signals due to four protons (OH) were not observed); ¹³C NMR (67.8 MHz, pyridine-*d*₅) δ 173.7, 157.5, 153.4, 150.7, 150.4, 141.1, 139.3, 137.7, 136.6, 127.7, 120.9, 115.6, 109.2, 107.1, 106.3, 103.5, 100.9, 74.8, 71.8, 71.4, 68.5, 64.4, 61.9, 58.4, 58.1; HRMS (ESI) *m/z* 557.1253, calcd for C₂₅H₂₆NaO₁₃ [M+Na]⁺ 557.1266.

4.1.17. 7-(Allyloxy)-3-(4,7-dimethoxybenzo[*d*][1,3]dioxol-5-yl)-6-methoxy-4*H*-chromen-4-one (26)

To a stirred solution of *O*⁷-demethyl analogue **22** (6.1 mg, 16.4 μ mol) in MeCN (0.16 mL) were added K₂CO₃ (4.5 mg, 32.6 μ mol) and allyl bromide (2.1 μ L, 23.6 μ mol) at room temperature. After being stirred at room temperature for 5 h, the mixture was diluted with saturated aqueous NaHCO₃ (1 mL) and extracted with CH₂Cl₂ (2 mL \times 3). The combined extracts were washed with brine (2 mL), dried (Na₂SO₄), and concentrated. The residual solid was purified by column chromatography on silica gel (0.6 g, hexane–EtOAc = 5:1 \rightarrow 3:1) to give allyl ether **26** (5.5 mg, 81%) as a white solid: IR (CHCl₃) 3008, 2938, 1639, 1607, 1503, 1469, 1430, 1267, 1099, 1063 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 7.89 (s, 1H), 7.62 (s, 1H), 6.89 (s, 1H), 6.52 (s, 1H), 6.11 (ddt, *J* = 17.6, 10.5, 5.4 Hz, 1H), 6.02 (s, 2H), 5.48 (ddt, *J* = 17.6, 1.4, 1.4 Hz, 1H), 5.38 (ddt, *J* = 10.5, 1.4, 1.4 Hz, 1H), 4.72 (dt, *J* = 5.4, 1.4 Hz, 2H), 3.98 (s, 3H), 3.87 (s, 3H), 3.85 (s, 3H); ¹³C NMR (67.8 MHz, CDCl₃) δ 175.2, 154.4, 153.4, 152.0, 147.8, 139.0, 138.9, 137.0, 136.6, 135.8, 121.5, 118.0, 117.7, 116.5, 110.0, 105.2, 101.8, 100.9, 73.3, 62.1, 57.0, 56.4; HRMS (ESI) *m/z* 435.1057, calcd for C₂₂H₂₀NaO₈ [M+Na]⁺ 435.1050.

4.1.18. 7-(2,3-Dihydroxypropoxy)-3-(4,7-dimethoxybenzo[*d*][1,3]dioxol-5-yl)-6-methoxy-4*H*-chromen-4-one (27)

To a stirred solution of allyl ether **26** (5.0 mg, 12.1 μ mol) in pyridine (0.12 mL) was added OsO₄ (0.4 M solution in THF, 0.04 mL, 16.0 μ mol) at room temperature. After being stirred at room temperature for 1.5 h, the reaction mixture was diluted with saturated aqueous NaHSO₃ (1 mL), stirred at room temperature for 1 h, and extracted with CH₂Cl₂ (1 mL \times 3). The combined extracts were washed with brine (2 mL), dried (Na₂SO₄), and concentrated. The residual solid was purified by column chromatography on silica gel (0.6 g, hexane–EtOAc = 1:1 \rightarrow 1:4) to give diol **27** (4.5 mg, 84%) as a white solid: IR (CHCl₃) 3508, 2968, 1637, 1608, 1505, 1458, 1267, 1101, 1060 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 7.91 (s, 1H), 7.62 (s, 1H), 6.92 (s, 1H), 6.52 (s, 1H), 6.03 (s, 2H), 4.28–4.19 (m, 5H), 3.96 (s, 3H), 3.87 (s, 3H), 3.86 (s, 3H), (Signals due to two protons (OH) was not observed); ¹³C NMR (67.8 MHz, CDCl₃) δ 175.3, 154.4, 153.4, 151.8, 147.6, 139.1, 138.9, 137.0, 136.6, 135.8, 121.5, 118.0, 117.7, 116.5, 110.0, 105.2, 101.8, 100.9, 73.3, 62.1, 57.0, 56.4; HRMS (ESI) *m/z* 435.1089, calcd for C₂₂H₂₂NaO₁₀ [M+Na]⁺ 469.1105.

4.1.19. 7-(Benzyloxy)-3-(4,7-dimethoxybenzo[*d*][1,3]dioxol-5-yl)-6-methoxy-4*H*-chromen-4-one (28)

To a stirred solution of *O*⁷-demethyl analogue **22** (6.8 mg, 18.3 μ mol) in MeCN (0.18 mL) were added K₂CO₃ (5.2 mg, 37.7 μ mol) and benzyl bromide (3.2 μ L, 26.9 μ mol). After being stirred at room temperature for 5 h, the mixture was diluted with saturated aqueous NaHCO₃ (1 mL) and extracted with CH₂Cl₂ (2 mL \times 3). The combined extracts were washed with brine (2 mL), dried (Na₂SO₄), and concentrated. The residual solid was purified by column chromatography on silica gel (0.6 g, hexane–EtOAc = 5:1 \rightarrow 3:1) to give benzyl ether **28** (6.8 mg, 80%) as a white solid: IR (CHCl₃) 3007, 2939, 1606, 1470, 1298, 1227, 1153, 1064 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 7.87 (s, 1H), 7.63 (s, 1H), 7.49–7.19 (m, 5H), 6.90 (s, 1H), 6.51 (s, 1H), 6.02 (s, 1H), 5.27 (s, 2H), 3.99 (s, 3H), 3.87 (s, 3H), 3.84 (s, 3H); ¹³C NMR (67.8 MHz, CDCl₃) δ 175.3, 153.3, 153.1, 151.9, 147.9, 139.0, 138.9, 137.0, 136.7, 135.4, 128.7 (2C), 128.3, 127.2 (2C), 121.6, 118.0, 117.9, 110.0, 105.1, 101.8, 101.3, 71.1, 60.2, 56.9, 56.4; HRMS (ESI) *m/z* 463.1379, calcd for C₂₆H₂₃O₈ [M+H]⁺ 463.1387.

4.1.20. 3-(4,7-Dimethoxybenzo[*d*][1,3]dioxol-5-yl)-6-methoxy-7-(prop-2-ynyloxy)-4*H*-chromen-4-one (29)

To a stirred solution of *O*⁷-demethyl analogue **22** (6.1 mg, 16.4 μ mol) in MeCN (0.16 mL) were added K₂CO₃ (4.5 mg, 32.6 μ mol) and propargyl bromide (2.1 μ L, 23.6 μ mol). After being stirred at room temperature for 5 h, the mixture was diluted with saturated aqueous NaHCO₃ (1 mL) and extracted with CH₂Cl₂ (2 mL \times 3). The combined extracts were washed with brine (2 mL), dried (Na₂SO₄), and concentrated. The residual solid was purified by column chromatography on silica gel (0.6 g, hexane–EtOAc = 5:1 \rightarrow 3:1) to give propargyl ether **29** (4.5 mg, 67%) as a white solid: IR (CHCl₃) 3306, 3008, 2934, 1638, 1609, 1502, 1470, 1431, 1398, 1267, 1231, 1209, 1099 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 7.92 (s, 1H), 7.64 (s, 1H), 7.08 (s, 1H), 6.52 (s, 1H), 6.03 (s, 2H), 4.90 (d, *J* = 2.2 Hz, 2H), 3.99 (s, 3H), 3.87 (s, 3H), 3.85 (s, 3H), 2.61 (s, 1H); ¹³C NMR (67.8 MHz, CDCl₃) δ 175.2, 153.5, 151.7, 147.8, 139.0, 138.9, 137.0, 136.7, 132.0, 121.7, 118.5, 117.9, 110.0, 105.4, 101.8, 101.6, 84.1, 77.2, 60.2, 60.1,

56.9, 56.4; HRMS (ESI) m/z 411.1068, calcd for $C_{22}H_{18}NaO_8$ $[M+H]^+$ 411.1074.

4.1.21. *tert*-Butyl 6-(6-(benzyloxy)hexanamido)hexylcarbamate (32)

To a stirred solution of 6-benzyloxyhexanoic acid **31** (97.3 mg, 450 μ mol) in DMF (3.5 mL) were added HOBt (67.3 mg, 499 μ mol) and DCC (103 mg, 500 μ mol) at 0 °C. After the mixture was stirred at 0 °C for 15 min, mono-Boc-1,6-diaminohexane **30** (107 mg, 461 μ mol) was added at 0 °C. After being stirred at room temperature for 12 h, the mixture was filtered and concentrated. The crude product was diluted with EtOAc (10 mL), washed with saturated aqueous $NaHCO_3$ (5 mL), water (5 mL), saturated aqueous NH_4Cl (5 mL), and brine (5 mL). The combined extracts were dried (Na_2SO_4) and concentrated. The residual oil was purified by column chromatography on silica gel (3.0 g, $CHCl_3$ -MeOH = 1:0 \rightarrow 20:1) to give amide **32** (153 mg, 81%) as a white solid: IR ($CHCl_3$) 3321, 3031, 2981, 1661, 1562, 1559, 1243 cm^{-1} ; 1H NMR (270 MHz, $CDCl_3$) δ 7.37–7.26 (m, 5H), 5.76 (br s, 1H), 4.61 (br s, 1H), 4.49 (s, 2H), 3.47 (t, J = 6.5 Hz, 2H), 3.21 (dt, J = 6.8, 6.5 Hz, 2H), 3.09 (dt, J = 6.8, 6.5 Hz, 2H), 2.16 (t, J = 7.3 Hz, 2H), 1.71–1.58 (m, 6H), 1.48–1.31 (m, 8H), 1.44 (s, 9H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 172.9, 156.1, 138.6, 128.3 (2C), 127.6 (2C), 127.5, 79.0, 72.9, 70.2, 40.2, 39.1, 36.7, 33.9, 30.0, 29.5, 28.4 (3C), 26.2, 26.0, 25.6, 25.5; HRMS (ESI) m/z 443.2880, calcd for $C_{24}H_{40}N_2NaO_4$ $[M+Na]^+$ 443.2880.

4.1.22. *tert*-Butyl 6-(6-hydroxyhexanamido)hexylcarbamate (32a)

To a stirred solution of amide **32** (153 mg, 364 μ mol) in EtOH (4.0 mL) was added 5% Pd/C (50% water wet, 80.0 mg) at room temperature. After being stirred at room temperature for 12 h under H_2 , the mixture was filtered through a pad of Celite and concentrated. The residual solid was purified by column chromatography on silica gel (2.5 g, $CHCl_3$ -MeOH = 100:1 \rightarrow 20:1) to give alcohol **32a** (107 mg, 89%) as a white solid: IR ($CHCl_3$) 3342, 2975, 1655, 1558 cm^{-1} ; 1H NMR (270 MHz, $CDCl_3$) δ 5.98 (br s, 1H), 4.67 (br s, 1H), 3.60 (t, J = 6.5 Hz, 2H), 3.19 (q, J = 6.5 Hz, 2H), 3.07 (q, J = 6.5 Hz, 2H), 2.16 (t, J = 7.2 Hz, 2H), 1.65 (quin, J = 7.2 Hz, 2H), 1.57 (quin, J = 6.5 Hz, 2H), 1.50–1.41 (m, 6H), 1.44 (s, 9H), 1.37–1.29 (m, 4H), (A signal due to one proton (OH) was not observed); ^{13}C NMR (125 MHz, $CDCl_3$) δ 173.0, 156.1, 79.1, 62.5, 40.1, 39.1, 36.6, 32.2, 29.9, 29.4, 28.4 (3C), 26.1, 26.0, 25.3, 25.1; HRMS (ESI) m/z 353.2423, calcd for $C_{17}H_{34}N_2NaO_4$ $[M+Na]^+$ 353.2411.

4.1.23. *tert*-Butyl 6-(6-bromohexanamido)hexylcarbamate (33)

To a stirred solution of alcohol **32a** (107 mg, 324 μ mol) in CH_2Cl_2 (3.2 mL) were added NBS (69.4 mg, 390 μ mol) and Ph_3P (102 mg, 389 μ mol) at room temperature. After being stirred at room temperature for 14 h, the mixture was diluted with water (5 mL) and extracted with CH_2Cl_2 (5 mL \times 3). The combined extracts were washed with brine (10 mL), dried (Na_2SO_4), and concentrated. The residual oil was purified by column chromatography on silica gel (5.0 g, $CHCl_3$ -MeOH = 100:1) to give bromide **33** (51.4 mg, 40%) as a white solid: IR ($CHCl_3$) 3327, 2970, 1649, 1553, 676 cm^{-1} ; 1H NMR (270 MHz, $CDCl_3$) δ 5.88 (br s, 1H), 4.61 (br s, 1H), 3.39 (t, J = 7.0 Hz, 2H), 3.21 (q, J = 6.5 Hz, 2H), 3.09 (q, J = 6.5 Hz, 2H), 2.17 (t, J = 7.3 Hz, 2H),

1.85 (quin, J = 7.0 Hz, 2H), 1.65 (quin, J = 7.3 Hz, 2H), 1.52–1.29 (m, 10H), 1.43 (s, 9H); ^{13}C NMR (67.8 MHz, $CDCl_3$) δ 171.8, 156.2, 79.4, 67.4, 40.5, 39.2, 36.6, 32.0, 29.7, 29.5, 28.9 (3C), 27.5, 26.7, 26.0, 25.5; HRMS (ESI) m/z 415.1569 calcd for $C_{17}H_{33}BrN_2NaO_3$ $[M+Na]^+$ 415.1567.

4.1.24. *tert*-Butyl 6-(6-(3-(4,7-dimethoxybenzo[*d*][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4*H*-chromen-7-yloxy)hexanamido)hexylcarbamate (33a)

To a stirred solution of *O*⁷-demethyl analogue **22** (6.9 mg, 18.5 μ mol) and bromide **33** (21.1 mg, 53.8 μ mol) in CH_2Cl_2 (0.27 mL) was added K_2CO_3 (7.4 mg, 53.6 μ mol) at 0 °C. After being stirred at reflux for 18 h, the mixture was diluted with water (1 mL) and extracted with CH_2Cl_2 (1 mL \times 3). The combined extracts were washed with brine (1 mL), dried (Na_2SO_4), and concentrated. The residual oil was purified by column chromatography on silica gel (0.6 g, hexane-EtOAc = 1:4) to give coupling compound **33a** (4.3 mg, 34%) as a white solid, and recovery of *O*⁷-demethyl analogue **22** (3.2 mg, 46%) as a white solid: IR ($CHCl_3$) 3344, 3020, 2967, 1657, 1600, 1568, 1502, 1288 cm^{-1} ; 1H NMR (270 MHz, $CDCl_3$) δ 7.89 (s, 1H), 7.60 (s, 1H), 6.86 (s, 1H), 6.52 (s, 1H), 6.02 (s, 2H), 5.64 (br s, 1H), 4.55 (br s, 1H), 4.10 (t, J = 7.0 Hz, 2H), 3.96 (s, 3H), 3.87 (s, 3H), 3.85 (s, 3H), 3.24 (q, J = 6.5 Hz, 2H), 3.10 (q, J = 6.5 Hz, 2H), 2.22 (t, J = 7.3 Hz, 2H), 1.95 (quin, J = 7.0 Hz, 2H), 1.80–1.70 (m, 2H), 1.57–1.23 (m, 10H), 1.44 (s, 9H); ^{13}C NMR (67.8 MHz, $CDCl_3$) δ 175.3, 171.6, 156.2, 153.8, 151.8, 151.6, 148.2, 139.1, 138.8, 137.1, 136.6, 121.2, 118.5, 117.6, 109.7, 105.3, 104.0, 102.0, 79.4, 67.4, 60.1, 56.9, 56.6, 40.5, 39.2, 37.5, 36.9, 36.6, 36.0, 32.0, 29.7, 29.5, 28.9 (3C), 25.5; HRMS (ESI) m/z 707.3139, calcd for $C_{36}H_{48}N_2NaO_{11}$ $[M+Na]^+$ 707.3150.

4.1.25. *N*-(6-Aminohexyl)-6-(3-(4,7-dimethoxybenzo[*d*][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4*H*-chromen-7-yloxy)hexanamide (34)

To a stirred solution of coupling compound **33a** (4.3 mg, 6.29 μ mol) in CH_2Cl_2 (0.10 mL) was added TFA (0.05 mL, 67.5 μ mol) at 0 °C. The mixture was stirred at room temperature for 4 h and concentrated. The residual oil was purified by column chromatography on silica gel (0.6 g, $CHCl_3$ -MeOH = 20:1 \rightarrow 10:1) to give amine **34** (TFA salt; 2.7 mg, 62%) as a white solid: IR ($CHCl_3$) 3326, 3024, 2980, 1648, 1591, 1554, 1510, 1285 cm^{-1} ; 1H NMR (270 MHz, $CDCl_3$) δ 7.89 (s, 1H), 7.57 (s, 1H), 6.85 (s, 1H), 6.50 (s, 1H), 6.20 (br s, 1H), 6.01 (s, 2H), 4.09 (t, J = 5.9 Hz, 2H), 3.94 (s, 3H), 3.86 (s, 3H), 3.84 (s, 3H), 3.20–3.13 (m, 2H), 2.96–2.90 (m, 2H), 2.20 (t, J = 7.3 Hz, 2H), 1.95–1.89 (m, 2H), 1.74–1.25 (m, 12H), (Signals due to two protons (NH) were not observed); ^{13}C NMR (67.8 MHz, $CDCl_3$) δ 175.2, 171.6, 153.8, 151.8, 151.6, 148.2, 139.1, 138.8, 137.1, 136.6, 121.2, 118.5, 117.6, 109.7, 105.3, 104.0, 102.0, 67.4, 60.1, 56.9, 56.6, 40.5, 39.2, 37.5, 36.7, 36.6, 36.0, 32.0, 29.7, 29.5, 25.5; HRMS (ESI) m/z 607.2638, calcd for $C_{31}H_{40}N_2NaO_9$ $[M+Na]^+$ 607.2626.

4.1.26. 6-(3-(4,7-Dimethoxybenzo[*d*][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4*H*-chromen-7-yloxy)-*N*-(6-(5-((3*aS*,4*S*,6*aR*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamido)hexyl)hexanamide (36)

To a stirred solution of amine **34** (2.7 mg, 3.87 μ mol) and (+)-biotin *N*-hydroxysuccinimide ester **35** (2.0 mg, 5.87 μ mol) in DMF (0.08 mL) was added Et_3N (3.0 μ L, 21.6 μ mol) at room

temperature. After being stirred at room temperature for 14 h, the mixture was diluted with brine (0.5 mL) and extracted with CH₂Cl₂ (1 mL×3). The combined extracts were dried (Na₂SO₄) and concentrated. The residual oil was purified by column chromatography on silica gel (0.6 g, CHCl₃–MeOH = 50:1 → 20:1) and by recycle HPLC [JAIGEL-1H-40 (600×20 mm) and JAIGEL-2H-40 (600×20 mm), flow rate 3.8 mL/min; detection, UV 265 nm; solvent CHCl₃] to give *O*⁷-biotinyl glaziovianin A (**36**) (2.7 mg, 41%) as a white solid: IR (CHCl₃) 3340, 3031, 2974, 1719, 1643, 1562, 1510, 1286, 1202 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 7.90 (s, 1H), 7.56 (s, 1H), 6.85 (s, 1H), 6.52 (s, 1H), 6.31 (br s, 1H), 6.16 (br s, 1H), 6.00 (s, 2H), 5.27 (s, 1H), 5.02 (s, 1H), 4.60–4.53 (m, 1H), 4.39–4.31 (m, 1H), 4.10 (t, *J* = 5.9 Hz, 2H), 3.95 (s, 3H), 3.87 (s, 3H), 3.85 (s, 3H), 3.25–3.09 (m, 5H), 2.94–2.89 (m, 2H), 2.31 (t, *J* = 7.3 Hz, 2H), 2.22 (t, *J* = 7.3 Hz, 2H), 1.84–1.33 (m, 20H); ¹³C NMR (125 MHz, CDCl₃) δ 178.8, 175.3, 171.4, 170.0, 153.8, 151.8, 151.5, 148.1, 139.1, 138.6, 137.0, 136.8, 121.2, 118.4, 117.5, 109.7, 105.3, 103.9, 102.1, 67.4, 60.0, 56.9, 56.7, 55.6, 53.9, 45.4, 40.7, 40.5, 39.1, 37.5, 37.0, 36.4, 35.9, 35.5, 32.3, 29.8, 29.5, 27.8, 26.7, 26.4, 25.5; HRMS (ESI) *m/z* 833.3385, calcd for C₄₁H₅₄N₄NaO₁₁S [M+Na]⁺ 833.3402.

4.1.27. (*E*)-Methyl 6-hydroxyhex-4-enoate (**38**)

To a stirred solution of aldehyde **37** (535 mg, 3.77 mmol) in MeOH (15 mL) was added NaBH₄ (171 mg, 4.52 mmol) at 0 °C. After being stirred at 0 °C for 1 h, the mixture was diluted with saturated aqueous NH₄Cl (8 mL) and water (30 mL) and extracted with CH₂Cl₂ (20 mL×3). The combined extracts were dried (Na₂SO₄) and concentrated. The residual oil was purified by column chromatography on silica gel (12 g, EtOAc–hexane = 3:1) to give allylic alcohol **38** (380 mg, 70%) as a white solid: IR (CHCl₃) 3340, 2986, 1739, 1670 cm⁻¹; ¹H NMR (270 MHz, CDCl₃) δ 5.71–5.68 (m, 2H), 4.34 (dt, *J* = 5.4, 1.6 Hz, 2H), 3.68 (s, 3H), 2.38 (t, *J* = 7.6 Hz, 2H), 2.18 (dt, *J* = 7.6, 5.1 Hz, 2H), (A signal due to one proton (OH) was not observed); ¹³C NMR (125 MHz, CDCl₃) δ 173.1, 132.5, 129.6, 74.2, 53.0, 33.5, 29.9; HRMS (ESI) *m/z* 167.0698, calcd for C₇H₁₂NaO₃ [M+Na]⁺ 167.0679.

4.1.28. (*E*)-Methyl 6-(*tert*-butyldimethylsilyloxy)hex-4-enoate (**39**)

To a stirred solution of allylic alcohol **38** (370 mg, 2.57 mmol) in DMF (26 mL) were added imidazole (385 mg, 5.65 mmol) and TBSCl (427 mg, 2.83 mmol) at room temperature. After being stirred at room temperature for 2 h, the mixture was diluted with water (10 mL) and extracted with EtOAc (15 mL×3). The combined extracts were washed with brine (10 mL), dried (Na₂SO₄), and concentrated. The residual oil was purified by column chromatography on silica gel (17 g, EtOAc–hexane = 30:1 → 10:1) to give TBS ether **39** (603 mg, 91%) as a white solid: IR (CHCl₃) 2978, 1743, 1661 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 5.72–5.64 (m, 2H), 4.21 (dt, *J* = 6.0, 1.4 Hz, 2H), 3.60 (s, 3H), 2.30 (t, *J* = 7.6 Hz, 2H), 2.16 (dt, *J* = 7.6, 5.2 Hz, 2H), 0.89 (s, 9H), 0.07 (s, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 173.2, 131.9, 128.5, 74.4, 53.2, 33.0, 29.6, 25.2 (3C), 18.4, –4.8 (2C); HRMS (ESI) *m/z* 281.1537, calcd for C₁₃H₂₆NaO₃Si [M+Na]⁺ 281.1543.

4.1.29. (*E*)-*tert*-Butyl 6-(6-(*tert*-butyldimethylsilyloxy)hex-4-enamido)hexylcarbamate (**40**)

To a stirred solution of TBS compound **39** (314 mg, 1.22 mmol) in toluene (4.1 mL) was added amine **30** (394 mg, 1.82 mmol) at room temperature. After being stirred at reflux for 24 h, the mixture was cooled to room temperature, diluted with water (5 mL), and extracted with CH₂Cl₂ (5 mL×3). The combined extracts were washed with brine (5 mL), dried (Na₂SO₄), and concentrated. The residual oil was purified by column chromatography on silica gel (18 g, CHCl₃–MeOH = 1:0 → 100:1) to give amide **40** (371 mg, 69%) as a white solid: IR (CHCl₃) 3375, 2968, 1661, 1652, 1568 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 5.92 (br s, 1H), 5.75–5.65 (m, 2H), 4.88 (br s, 1H), 4.21 (dt, *J* = 6.3, 1.5 Hz, 2H), 3.27 (q, *J* = 6.0 Hz, 2H), 3.16 (q, *J* = 6.0 Hz, 2H), 2.22 (t, *J* = 7.8 Hz, 2H), 2.16 (dt, *J* = 7.8, 5.8 Hz, 2H), 1.51–1.46 (m, 4H), 1.40 (s, 9H), 1.34–1.30 (m, 4H), 0.89 (s, 9H), 0.07 (s, 6H); ¹³C NMR (125 MHz, CDCl₃) δ 173.7, 157.0, 132.0, 128.5, 78.6, 74.6, 41.1, 40.2, 34.0, 29.9, 29.3, 29.1, 28.3 (3C), 25.7, 25.5, 25.2 (3C), 18.4, –4.8 (2C); HRMS (ESI) *m/z* 465.3117, calcd for C₂₃H₄₆N₂NaO₄Si [M+Na]⁺ 465.3119.

4.1.30. (*E*)-*tert*-Butyl 6-(6-hydroxyhex-4-enamido)hexylcarbamate (**41**)

To a stirred solution of TBS ether **40** (360 mg, 814 μmol) in THF (8.1 mL) was added TBAF (276 mg, 1.06 mmol) at room temperature. After being stirred at room temperature for 4 h, the mixture was diluted with saturated NH₄Cl (7 mL) and extracted with CH₂Cl₂ (8 mL×3). The combined extracts were washed with brine (10 mL), dried (Na₂SO₄), and concentrated. The residual oil was purified by column chromatography on silica gel (10 g, CHCl₃–MeOH = 50:1 → 20:1) to give allylic alcohol **41** (230 mg, 86%) as a white solid: IR (CHCl₃) 3362, 2972, 1669, 1649, 1551 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 5.81–5.70 (m, 3H), 4.79 (br s, 1H), 4.25 (dt, *J* = 5.2, 1.9 Hz, 2H), 3.27 (q, *J* = 6.0 Hz, 2H), 3.19 (q, *J* = 6.0 Hz, 2H), 2.20 (t, *J* = 7.5 Hz, 2H), 2.15 (dt, *J* = 7.5, 5.4 Hz, 2H), 1.51–1.47 (m, 4H), 1.43 (s, 9H), 1.36–1.30 (m, 4H), (A signal due to one proton (OH) was not observed); ¹³C NMR (125 MHz, CDCl₃) δ 173.5, 156.9, 132.3, 128.5, 78.4, 74.6, 41.1, 40.0, 33.7, 29.6, 29.3, 29.0, 28.2 (3C), 25.9, 25.6; HRMS (ESI) *m/z* 351.2281, calcd for C₁₇H₃₂N₂NaO₄ [M+Na]⁺ 351.2254.

4.1.31. (*E*)-*tert*-Butyl 6-(6-bromohex-4-enamido)hexylcarbamate (**42**)

To a stirred solution of allylic alcohol **41** (222 mg, 677 μmol) in CH₂Cl₂ (6.8 mL) were added Ph₃P (213 mg, 813 μmol) and NBS (145 mg, 815 μmol) at room temperature. After being stirred at room temperature for 13 h, the mixture was diluted with water (5 mL) and extracted with CH₂Cl₂ (7 mL×3). The combined extracts were washed with brine (10 mL), dried (Na₂SO₄), and concentrated. The residual oil was purified by column chromatography on silica gel (13 g, CHCl₃–MeOH = 1:0 → 100:1) to give allylic bromide **42** (169 mg, 64%) as a white solid: IR (CHCl₃) 3368, 2976, 1660, 1642, 1539, 691 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 5.82 (br s, 1H), 5.69–5.65 (m, 2H), 4.69 (br s, 1H), 4.03 (dt, *J* = 5.7, 1.6 Hz, 2H), 3.26 (q, *J* = 5.9 Hz, 2H), 3.20 (q, *J* = 5.6 Hz, 2H), 2.20 (t, *J* = 7.7 Hz, 2H), 2.12 (dt, *J* = 7.7, 5.5 Hz, 2H), 1.55–1.48 (m, 4H), 1.45 (s, 9H), 1.37–1.29 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 173.6, 157.1, 129.7, 126.9, 78.5, 69.2, 41.1, 40.6, 33.8, 29.5, 29.1, 28.7, 28.2 (3C), 26.0, 25.5; HRMS (ESI) *m/z* 413.1404, calcd for C₁₇H₃₁BrN₂NaO₃ [M+Na]⁺ 413.1410.

4.1.32. (*E*)-*tert*-Butyl 6-(6-(3-(4,7-dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4*H*-chromen-7-yl)oxy)hex-4-enamido)hexylcarbamate (43)

To a stirred solution of *O*⁷-demethyl analogue **22** (10.3 mg, 27.7 μmol) and allylic bromide **42** (19.2 mg, 58.5 μmol) in MeCN (0.28 mL) was added K₂CO₃ (9.4 mg, 68.1 μmol) at room temperature. After being stirred at reflux for 13 h, the mixture was cooled to room temperature, diluted with saturated NH₄Cl (0.5 mL), and extracted with CH₂Cl₂ (1 mL×3). The combined extracts were washed with brine (2 mL), dried (Na₂SO₄), and concentrated. The residual oil was purified by column chromatography on silica gel (0.6 g, CHCl₃-MeOH = 400:1 → 100:1) to give coupling compound **43** (11.0 mg, 72%) as a white solid, and recovery of phenol **22** (1.4 mg, 14%) as a white solid: IR (CHCl₃) 3356, 3024, 2985, 1676, 1660, 1611, 1575, 1499, 1282 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.90 (s, 1H), 7.60 (s, 1H), 6.85 (s, 1H), 6.52 (s, 1H), 6.00 (s, 2H), 5.86–5.80 (m, 3H), 4.62 (br s, 1H), 4.48 (dt, *J* = 7.0, 1.8 Hz, 2H), 3.96 (s, 3H), 3.87 (s, 3H), 3.85 (s, 3H), 3.27 (q, *J* = 6.3 Hz, 2H), 3.19 (q, *J* = 6.3 Hz, 2H), 2.25 (t, *J* = 7.3 Hz, 2H), 2.02 (dt, *J* = 7.3, 5.2 Hz, 2H), 1.58–1.50 (m, 4H), 1.44 (s, 9H), 1.35–1.29 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 175.5, 171.4, 156.4, 153.8, 151.8, 151.2, 147.7, 138.9, 138.7, 137.1, 136.5, 136.3, 132.5, 121.2, 118.4, 117.1, 109.5, 105.0, 104.0, 102.2, 79.6, 77.6, 60.0, 56.9, 56.7, 39.8, 39.2, 36.9, 36.0, 31.8, 31.4, 29.4, 28.7 (3C), 25.3; HRMS (ESI) *m/z* 705.2996, calcd for C₃₆H₄₆N₂NaO₁₁ [M+Na]⁺ 705.2994.

4.1.33. (*E*)-*N*-(6-Aminoheptyl)-6-(3-(4,7-dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4*H*-chromen-7-yl)oxy)hex-4-enamide (44)

To a stirred solution of coupling compound **43** (8.0 mg, 11.7 μmol) in CH₂Cl₂ (0.20 mL) was added TFA (0.010 mL, 135 μmol) at 0 °C. The mixture was stirred at room temperature for 3 h and concentrated. The residual solid was purified by column chromatography on silica gel (0.6 g, CHCl₃-MeOH = 20:1 → 10:1) to give amine **44** (TFA salt; 4.4 mg, 55%) as a white solid: IR (CHCl₃) 3339, 3030, 2978, 1672, 1654, 1607, 1562, 1510, 1293 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.90 (s, 1H), 7.61 (s, 1H), 6.85 (s, 1H), 6.55 (s, 1H), 6.13 (br s, 1H), 6.01 (s, 2H), 5.82–5.76 (m, 2H), 4.47 (dt, *J* = 7.2, 1.6 Hz, 2H), 3.95 (s, 3H), 3.87 (s, 3H), 3.84 (s, 3H), 3.27–3.21 (m, 2H), 2.95–2.90 (m, 2H), 2.29 (t, *J* = 7.4 Hz, 2H), 2.07 (dt, *J* = 7.4, 5.4 Hz, 2H), 1.63–1.55 (m, 4H), 1.36–1.30 (m, 4H), (Signals due to two protons (NH) were not observed); ¹³C NMR (125 MHz, CDCl₃) δ 175.8, 171.4, 153.8, 152.1, 151.5, 147.3, 138.9, 138.7, 137.1, 136.4, 136.1, 132.7, 121.1, 118.2, 117.1, 109.5, 105.0, 104.0, 102.0, 77.5, 60.3, 56.9, 56.5, 40.1, 39.4, 36.6, 35.8, 31.7, 31.4, 29.4, 25.2; HRMS (ESI) *m/z* 605.2480, calcd for C₃₁H₃₈N₂NaO₉ [M+Na]⁺ 605.2470.

4.1.34. (*E*)-6-(3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4*H*-chromen-7-yl)oxy)-*N*-(6-(5-((3*aS*,6*aR*)-2-oxohexahydro-1*H*-thieno[3,4-*d*]imidazol-4-yl)pentanamido)hexyl)hex-4-enamide (45)

To a stirred solution of amine **44** (2.8 mg, 4.02 μmol) and (+)-biotin *N*-hydroxysuccinimide ester **35** (2.1 mg, 6.16 μmol) in DMF (0.08 mL) was added Et₃N (2.8 μL, 20.2 μmol) at room temperature. After being stirred at room temperature for 16 h, the mixture was diluted with brine (0.5 mL) and extracted with CH₂Cl₂ (1 mL×3). The combined extracts were dried (Na₂SO₄) and concentrated. The residual oil was purified by column

chromatography on silica gel (0.6 g, CHCl₃-MeOH = 50:1 → 20:1) and by recycle HPLC [JAIGEL-1H-40 (600×20 mm) and JAIGEL-2H-40 (600×20 mm), flow rate 3.8 mL/min; detection, UV 265 nm; solvent CHCl₃] to give *O*⁷-modified biotin probe **45** (1.5 mg, 47%) as a white solid: IR (CHCl₃) 3350, 3020, 2982, 1723, 1673, 1650, 1607, 1574, 1286, 1199 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.90 (s, 1H), 7.60 (s, 1H), 6.82 (s, 1H), 6.56 (s, 1H), 6.15 (br s, 1H), 6.04 (br s, 1H), 6.02 (s, 2H), 5.81–5.76 (m, 2H), 5.23 (s, 1H), 4.97 (s, 1H), 4.62–4.57 (m, 1H), 4.44 (dt, *J* = 7.0, 1.5 Hz, 2H), 4.36–4.32 (m, 1H), 3.96 (s, 3H), 3.87 (s, 3H), 3.85 (s, 3H), 3.27–3.13 (m, 5H), 2.93–2.88 (m, 2H), 2.33 (t, *J* = 7.2 Hz, 2H), 2.24 (t, *J* = 7.6 Hz, 2H), 2.07 (dt, *J* = 7.6, 5.2 Hz, 2H), 1.87–1.70 (m, 4H), 1.65–1.50 (m, 6H), 1.35–1.29 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 179.0, 175.8, 171.2, 169.7, 154.0, 152.1, 151.5, 147.5, 139.0, 138.8, 137.1, 136.1, 135.7, 132.8, 121.0, 118.4, 117.1, 109.5, 105.4, 104.1, 101.8, 77.9, 60.1, 56.9, 56.6, 55.4, 54.0, 45.4, 40.5, 39.4, 37.2, 36.6, 35.8, 35.3, 32.0, 31.4, 29.6, 27.7, 26.7, 26.1, 25.5; HRMS (ESI) *m/z* 831.3241, calcd for C₄₁H₅₂N₄NaO₁₁S [M+Na]⁺ 831.3245.

4.1.35. (*E*)-*N*-(6-(3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4*H*-chromen-7-yl)oxy)hex-4-enamido)hexyl-4-(3-(trifluoromethyl)-3*H*-diazirin-3-yl)benzamide (46)

To a stirred solution of amine **44** (2.1 mg, 3.02 μmol) and 3-trifluoromethyl-3-phenyldiazirine succinimide ester **48** (1.5 mg, 4.59 μmol) in MeCN (0.06 mL) was added Et₃N (2.0 μL, 14.4 μmol) at room temperature. After being stirred at room temperature for 24 h, the mixture was diluted with brine (0.5 mL) and extracted with CH₂Cl₂ (1 mL×3). The combined extracts were dried (Na₂SO₄) and concentrated. The residual oil was purified by column chromatography on silica gel (0.6 g, CHCl₃-MeOH = 300:1 → 100:1) to give *O*⁷-modified photoaffinity probe **46** (1.2 mg, 49%) as a white solid: IR (CHCl₃) 3345, 3028, 2980, 1672, 1658, 1602, 1578, 1559, 1514, 1288 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.98 (d, *J* = 8.0 Hz, 2H), 7.89 (s, 1H), 7.63 (s, 1H), 7.19 (d, *J* = 8.0 Hz, 2H), 6.86 (s, 1H), 6.51 (s, 1H), 6.30 (br s, 1H), 6.13 (br s, 1H), 6.02 (s, 2H), 5.85–5.79 (m, 2H), 4.47 (dt, *J* = 7.0, 1.8 Hz, 2H), 3.98 (s, 3H), 3.87 (s, 3H), 3.84 (s, 3H), 3.37–3.25 (m, 4H), 2.26 (t, *J* = 7.5 Hz, 2H), 2.05 (dt, *J* = 7.5, 5.0 Hz, 2H), 1.64–1.55 (m, 4H), 1.38–1.30 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 176.0, 172.4, 171.1, 153.8, 152.5, 151.7, 147.3, 139.0, 138.6, 137.2, 136.4, 135.9, 134.8, 132.7, 130.2 (2C), 130.0, 126.7 (2C), 122.9 (q, ¹*J*_{C,F} = 275 Hz), 121.1, 118.4, 117.2, 109.7, 104.9, 104.1, 102.0, 77.2, 60.3, 57.0, 56.6, 39.6, 39.3, 36.5, 35.9, 31.7, 31.4, 29.5, 28.4 (q, ²*J*_{C,F} = 50.0 Hz), 25.2; HRMS (ESI) *m/z* 817.2675, calcd for C₄₀H₄₁F₃N₄NaO₁₀ [M+Na]⁺ 817.2667.

4.1.36. (*E*)-10-(4-(6-(3-(4,7-Dimethoxybenzo[d][1,3]dioxol-5-yl)-6-methoxy-4-oxo-4*H*-chromen-7-yl)oxy)hex-4-enamido)hexylamino)-4-oxobutyl)-5,5-difluoro-1,3,7,9-tetramethyl-5*H*-dipyrrolo[1,2-*c*:1',2'-*f*][1,3,2]diazaborinin-4-ium-5-uide (47)

To a stirred solution of amine **44** (1.4 mg, 2.05 μmol) and BODIPY succinimide ester **49** (1.4 mg, 3.25 μmol) in MeCN (0.05 mL) was added Et₃N (1.5 μL, 10.8 μmol) at room temperature. After being stirred at room temperature for 24 h, the mixture was diluted with brine (0.5 mL) and extracted with CH₂Cl₂ (1 mL×3). The combined extracts were dried (Na₂SO₄) and concentrated. The residual oil was purified by column chromatography on silica gel (0.6 g, CHCl₃-MeOH = 100:1 → 40:1) and by recycle HPLC [JAIGEL-1H-40 (600×20 mm) and

JAIGEL-2H-40 (600×20 mm), flow rate 3.8 mL/min; detection, UV 265 nm; solvent CHCl₃] to give *O*⁷-modified fluorescent probe **47** (1.2 mg, 65%) as a white solid: IR (CHCl₃) 3358, 3025, 3019, 2982, 2850, 1665, 1653, 1607, 1555, 1294 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 7.90 (s, 1H), 7.61 (s, 1H), 6.84 (s, 1H), 6.55 (s, 1H), 6.22 (br s, 1H), 6.11 (br s, 1H), 6.06 (s, 2H), 6.02 (s, 2H), 5.80–5.74 (m, 2H), 4.45 (dt, *J* = 7.2, 1.6 Hz, 2H), 3.96 (s, 3H), 3.86 (s, 3H), 3.84 (s, 3H), 3.28–3.20 (m, 4H), 3.05 (t, *J* = 8.4 Hz, 2H), 2.52 (s, 6H), 2.45 (s, 6H), 2.41 (t, *J* = 7.0 Hz, 2H), 2.28 (t, *J* = 7.4 Hz, 2H), 2.05–1.98 (m, 4H), 1.65–1.59 (m, 4H), 1.36–1.29 (m, 4H); ¹³C NMR (125 MHz, CDCl₃) δ 175.8, 173.9, 171.7, 154.3, 153.9, 152.0, 151.2, 147.3, 144.7 (2C), 140.4 (2C), 139.1, 138.7, 137.4, 136.4, 136.0, 132.6, 131.5 (2C), 121.9 (2C), 120.9, 118.2, 117.1, 109.4, 105.1, 104.3, 101.8, 77.8, 60.0, 56.8, 56.5, 40.1, 39.5, 36.4, 35.8, 31.5, 31.2, 30.5, 29.4, 27.4, 26.5, 25.1, 16.3 (2C), 14.4 (2C); HRMS (ESI) *m/z* 921.4025, calcd for C₄₈H₅₇BF₂N₄NaO₁₀ [M+Na]⁺ 921.4028.

4.2. Bioassay

Cell survival was determined by a WST-8 assay kit (Dojindo Laboratories, Kumamoto, Japan). HeLa S₃ cells (3×10³ cells/well) in 96 well plates were incubated overnight. Then, cells were treated with various concentrations of each compound. After 48 h incubation, 10 μL of WST-8 reagents were added to the culture. After 2 h incubation, the absorbance at 450 nm was measured with iMark microplate reader (BioRad Laboratories, Inc). Absorbance correlates with the number of living cells. The number of living cells (% control) was calculated with the following formula: (each absorbance - absorbance of blank well) / (absorbance of 0 μM well - absorbance of blank well) × 100.

4.3. Cell culture and reagents

Human cervix epidermoid carcinoma HeLa S₃ cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal-calf serum (FCS, Cell Culture Bioscience). Cells were grown at 37 °C in a 5% CO₂ atmosphere. Antibodies specific for α-tubulin (DM1A, #sc-32293) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Alexa488-conjugated anti-mouse IgG antibody (#A11001) was purchased from Invitrogen. DAPI solution was purchased from Wako Pure Chemical Industry (Osaka, Japan).

4.3.1. Analysis of cell cycle progression

3×10⁴ cells/mL HeLa S₃ cells were treated with various concentrations of each compound for 24 h, then harvested and fixed with 70% EtOH (−20 °C). After staining with propidium iodide solution, DNA contents were measured by flow cytometric analysis (Attune[®] Acoustic Focusing Cytometer; Applied Biosystems).

4.3.2. Immunofluorescence procedures

3×10⁴ cells/mL HeLa S₃ cells were seeded on sterile coverslips. After treatment of each compound for 6 h, coverslips were fixed with −20 °C MeOH for 5 min. After being washed with PBS-B (PBS containing 0.5% (w/v) BSA), coverslips were overlaid with anti-α-tubulin antibody in PBS-B then placed in a humidified container at 37 °C and incubated for 1 h. After being washed twice with PBS-B, coverslips were overlaid with Alexa488-

conjugated anti-mouse IgG antibody in PBS-B, incubated for 1 h, washed with PBS and mounted with 0.1 μg/mL DAPI solution. The morphology of microtubule and nuclei were observed under a Leica LAS AF 6000 fluorescent microscope (Leica Microsystems GmbH, Wetzlar, Germany). Dilutions of antibodies were 1:250 (antibodies specific for α-tubulin) and 1:2000 (Alexa488-conjugated anti-mouse IgG antibody).

Acknowledgments

This work was supported by Grants-in-Aid for Scientific Research on Innovative Areas "Chemical Biology of Natural Products" and for Scientific Research (B) from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) / Japanese Society for the Promotion of Science (JSPS); by a grant from the Uehara Memorial Foundation; and by a grant from the University of Tsukuba, Strategic Initiatives (A), Center for Creation of Functional Materials (CCFM). I.H. thanks The Society of Synthetic Organic Chemistry, Japan (Meiji Seika Award in Synthetic Organic Chemistry, Japan) and the Suntory Institute for Bioorganic Research (SUNBOR GRANT) for their financial support.

Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.bmc.XXXX.XX.XXX>.

References and notes

- Yokosuka, A.; Haraguchi, M.; Usui, T.; Kazami, S.; Osada, H.; Yamori, T.; Mimaki, Y. *Bioorg. Med. Chem. Lett.* **2007**, *17*, 3091.
- Yamori, T.; Matsunaga, A.; Saito, S.; Yamazaki, K.; Komi, A.; Ishizu, K.; Mita, I.; Edatsugi, H.; Matsuda, Y.; Takezawa, K.; Nakanishi, O.; Kohno, H.; Nakajima, Y.; Komatsu, H.; Andoh, T.; Tsuruo, T. *Cancer Res.* **1999**, *59*, 4042.
- Review: Kingston, D. G. I. *J. Nat. Prod.* **2009**, *72*, 507.
- Ikeda, A.; Hayakawa, I.; Usui, T.; Kazami, S.; Osada, H.; Kigoshi, H. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 5402.
- Hayakawa, I.; Ikeda, A.; Kigoshi, H. *Chem. Lett.* **2007**, *36*, 1382.
- Piggott, M. J.; Wege, D. *Aust. J. Chem.* **2000**, *53*, 749.
- Ishiyama, T.; Murata, M.; Miyaura, N. *J. Org. Chem.* **1995**, *60*, 7508.
- Hoshino, Y.; Miyaura, N.; Suzuki, A. *Bull. Chem. Soc. Jpn.* **1988**, *61*, 3008.
- Tremblay, S. M.; Sames, D. *Org. Lett.* **2005**, *7*, 2417.
- Adityachaudhury, N.; Kirtaniya, C. L.; Mukherjee, B. *Tetrahedron* **1971**, *27*, 2111.
- Gammill, R. B. *Synthesis* **1979**, 901.
- Igarashi, Y.; Kumazawa, H.; Ohshima, T.; Satomi, H.; Terabayashi, S.; Takeda, S.; Aburada, M.; Miyamoto, K. *Chem. Pharm. Bull.* **2005**, *53*, 1088.
- Schmidt, R. R.; Michel, J. *Angew. Chem. Int. Ed.* **1980**, *19*, 731.
- The calculated Log P (cLog P) values of glaziovianin A and its analogues were obtained by using ChemBioDraw Ultra 11.0 (CambridgeSoft): Hansch, C.; Fujita, T. *J. Am. Chem. Soc.* **1964**, *86*, 1616.
- Although we previously reported the IC₅₀ values of compounds **26**, **28**, and **29** to be 0.19, 0.75 and 0.74 μM, respectively,⁴ we have reevaluated their cytotoxicities against HeLa S₃ cells and found that those IC₅₀ values should be corrected as described in this paper.
- Kondoh, M.; Usui, T.; Nishikiori, T.; Mayumi, T.; Osada, H. *Biochem. J.* **1999**, *340*, 411.
- Although we previously reported the effects of glaziovianin A (**1**) and compound **26** on cell cycle progression and spindle

structures,⁴ we have reevaluated their effects along with compounds **28** and **29** and found that those effects should be corrected as described in this paper.

18. Callahan, J. F.; Ashton-Shue, D.; Bryan, H. G.; Bryan, W. M.; Heckman, G. D.; Kinter, L. B.; McDonald, J. E.; Moore, M. L.; Schmidt, D. B.; Silvestri, J. S.; Stassen, F. L.; Sulat, L.; Yim, N. C. F.; Huffman, W. F. *J. Med. Chem.* **1989**, *32*, 391.
19. Lermer, L.; Neeland, E. G.; Ounsworth, J. P.; Sims, R. J.; Tischler, S. A.; Weiler, L. *Can. J. Chem.* **1992**, *70*, 1427.
20. Becker, J. M.; Wilchek, M. *Biochim. Biophys. Acta.* **1972**, *264*, 165.
21. Ku, T. W.; McCarthy, M. E.; Weichman, B. M.; Gleason, J. G. *J. Med. Chem.* **1985**, *28*, 1847.
22. (a) Stromgaard, K.; Saito, R. D.; Shindou, H.; Ishii, S.; Shimizu, T.; Nakanishi, K. *J. Med. Chem.* **2002**, *45*, 4038. (b) Nassal, M. *Liebigs Ann. Chem.* **1983**, 1510.
23. (a) Li, Z.; Mintzer, E.; Bittman, R. *J. Org. Chem.* **2006**, *71*, 1718. (b) Tera, M.; Iida, K.; Ikebukuro, K.; Seimiya, H.; Shin-ya, K.; Nagasawa, K. *Org. Biomol. Chem.* **2010**, *8*, 2749.

[Click here to remove instruction text...](#)